Alpha-proteinase inhibitor
Phase 2Small molecule
Alpha-proteinase inhibitor is one of 15 small molecule programs targeting Eosinophilic Esophagitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Eosinophilic Esophagitis
#DrugCompanyPhaseTrials
1Pulmicort
SSalix
Approved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Flovent
PParatek Pharmaceuticals Inc
Approved
Prevacid
TakedaApproved
Flovent
PParatek Pharmaceuticals Inc
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Tezspire
AstraZenecaPhase 3
CC-93538
Bristol-Myers SquibbPhase 3
Omeprazole BID
UUniversity of Colorado, Denver
Phase 3
Alpha-proteinase inhibitor
CChildren's Hospital Medical Center, Cincinnati
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Eosinophilic Esophagitis1 trial
Zemaira Eosinophilic Esophagitis Pilot Study
Recruiting·—·Phase 2·NCT05485155·15 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alpha-proteinase inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details